Guidance Targets Overfilling of Vials, Ampules
The FDA wants manufacturers to better control the amount of excess drug or biologic they put in injectable vials and ampules to ensure proper patient dosing.
According to final guidance released June 24, it’s okay for the volume of product to vary somewhat, but more than slight variations in amount of product should be justified.
The FDA considers the net quantity listed on the label to mean the minimum quantity of contents. Excess volume greater or less than the U.S. Pharmacopoeia’s recommended amount, without proper justification, could lead to medication errors, misuse of leftover drug product or combining vials to get a single dose, which could lead to contamination, the guidance says.
The guidance applies to NDAs, ANDAs, BLAs, as well as supplements or changes to those applications for new packaging or other changes that may affect fill volume.
Companies needing to fill a vial fuller than is recommended should refer to the USP’s General Chapter <1151> on injections, the FDA says. This means designing a product to “meet the label claim and acceptable overfill, and allow for correct dosing,” the guidance says.
Stay up to date on regulatory stories like this one by subscribing to the Drug GMP Report. For over 20 years, drug manufacturers have relied on DGR for the latest on FDA’s interpretation and enforcement of cGMPs and the Quality Systems Regulation — information you need to stay in compliance.